Tyler J. Varisco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tyler J. Varisco has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- James Douglas Thornton
Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX 77204, USA
17 shared publications - Matthew A. Wanat
University of Houston College of Pharmacy, TX, USA
7 shared publications Douglas Thornton
5 shared publications- Marc L. Fleming
Assistant Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, Texas
5 shared publications Matthew A. Wanat
The Prescription Drug Misuse Education and Research Center, University of Houston College of Pharmacy, USA
4 shared publicationsAbolfazl Sadeghi
3 shared publications
Latest Publications
- Open Access
- 9 May 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 19
The development of a patient-reported outcome measuring opioid use disorder financial toxicity: Establishing content validity and reliability
- 9 May 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 19
Open AccessThe development of a patient-reported outcome measuring opioid use disorder financial toxicity: Establishing content validity and reliability
- Open Access
- 24 November 2025
- Published by Springer Nature in Cardiology and Therapy
- Vol. 14 (4) , 671-685
Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up
Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeutic agent, offers a promising solution by lowering LDL-C with twice-yearly dosing after an initial and 3-month dose. The study objective was to evaluate adherence to inclisiran and its lipid-lowering effectiveness over a year of treatment. Methods This retrospective cohort study involved patients over 18 years old with ASCVD or hyperlipidemia who initiated inclisiran between January 1, 2022, and May 17, 2023, in US outpatient clinics. LDL-C reduction was evaluated in patients with ≥ 1 pre- and post-index LDL-C measurement by comparing baseline levels to the lowest value within 12 months after initiating inclisiran. Results Overall, 225 patients initiated inclisiran. The mean age was 69.9 years and 50.7% were female. Most patients (81.8%) had ASCVD. Most patients (91.6%) received a second dose, and 84.5% of these received a third dose. Overall, 202 patients had ≥ 2 LDL-C measurements, with a mean baseline LDL-C of 134.8 mg/dl. Mean absolute LDL-C reduction was 66.1 (standard deviation: 45.6) mg/dl, corresponding to a 46.8% (95% confidence interval: 42.7–51.0) relative reduction, and 46.8% achieved ≥ 50% reduction. Patients on concurrent statins and those without prior anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibodies experienced the largest relative LDL-C reductions: 55.4% and 51.1%, respectively. Conclusions Inclisiran significantly reduced LDL-C. The dosing schedule promoted high adherence in a real-world setting, particularly among older adults with ASCVD. These findings indicate inclisiran may be a particularly valuable addition to lipid-lowering strategies.
- 24 November 2025
- Published by Springer Nature in Cardiology and Therapy
- Vol. 14 (4) , 671-685
Open AccessReal-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up
Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeutic agent, offers a promising solution by lowering LDL-C with twice-yearly dosing after an initial and 3-month dose. The study objective was to evaluate adherence to inclisiran and its lipid-lowering effectiveness over a year of treatment. Methods This retrospective cohort study involved patients over 18 years old with ASCVD or hyperlipidemia who initiated inclisiran between January 1, 2022, and May 17, 2023, in US outpatient clinics. LDL-C reduction was evaluated in patients with ≥ 1 pre- and post-index LDL-C measurement by comparing baseline levels to the lowest value within 12 months after initiating inclisiran. Results Overall, 225 patients initiated inclisiran. The mean age was 69.9 years and 50.7% were female. Most patients (81.8%) had ASCVD. Most patients (91.6%) received a second dose, and 84.5% of these received a third dose. Overall, 202 patients had ≥ 2 LDL-C measurements, with a mean baseline LDL-C of 134.8 mg/dl. Mean absolute LDL-C reduction was 66.1 (standard deviation: 45.6) mg/dl, corresponding to a 46.8% (95% confidence interval: 42.7–51.0) relative reduction, and 46.8% achieved ≥ 50% reduction. Patients on concurrent statins and those without prior anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibodies experienced the largest relative LDL-C reductions: 55.4% and 51.1%, respectively. Conclusions Inclisiran significantly reduced LDL-C. The dosing schedule promoted high adherence in a real-world setting, particularly among older adults with ASCVD. These findings indicate inclisiran may be a particularly valuable addition to lipid-lowering strategies.
- 20 October 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 180, 209818
Gaps in buprenorphine access: Examining provider availability and treatment continuity
- 20 October 2025
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 180, 209818
Gaps in buprenorphine access: Examining provider availability and treatment continuity
- 11 September 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (7) , 1907-1919
Buprenorphine Adherence Trajectories and Their Impact on Opioid Overdose and Healthcare Costs
Introduction: Buprenorphine is effective for opioid use disorder (OUD), yet adherence remains suboptimal. This study aimed to identify adherence trajectories, explore their predictors, and assess their association with opioid overdose risk and healthcare costs. Methods: A retrospective cohort study was conducted using the Merative MarketScan Commercial Database, which includes a nationally representative sample of individuals with private, employer‐sponsored health insurance in the United States. We included adults (≥ 16 years) with OUD who initiated and completed at least 30 consecutive days of buprenorphine treatment between July 2017 and June 2019, with a 180‐day follow‐up. Group‐based trajectory modelling identified distinct adherence patterns. Multinomial logistic regression examined predictors of adherence trajectories. A discrete‐time survival model estimated the association between adherence and opioid overdose risk, while generalised linear models assessed healthcare costs. Sensitivity analyses, including E‐value calculations, evaluated residual confounding. Results: Among the 5107 individuals (median [Q1‐Q3] age in years: 37 [26–47]; 3185 [62.4%] male), three distinct buprenorphine adherence trajectories were identified in the follow‐up period: consistent adherence (CA, 49.5%), slow‐declining adherence (SDA, 28.0%) and rapidly‐declining adherence (RDA, 22.5%) trajectory groups. The mean (95% CI) time to buprenorphine discontinuation among all beneficiaries was 153 (151–155) days. Compared to the CA group, SDA and RDA groups had 2.74 (95% CI 2.71–2.77) and 3.81 (95% CI: 3.76–3.86) times higher opioid overdose risk and $13,670 (95% CI $7644–$19,695) and $19,431 (95% CI $13,632–$25,229) higher healthcare spending, respectively. Discussion and Conclusions: Consistent adherence to buprenorphine was associated with a lower risk of opioid overdose and reduced healthcare expenditures.
- 11 September 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (7) , 1907-1919
Buprenorphine Adherence Trajectories and Their Impact on Opioid Overdose and Healthcare Costs
Introduction: Buprenorphine is effective for opioid use disorder (OUD), yet adherence remains suboptimal. This study aimed to identify adherence trajectories, explore their predictors, and assess their association with opioid overdose risk and healthcare costs. Methods: A retrospective cohort study was conducted using the Merative MarketScan Commercial Database, which includes a nationally representative sample of individuals with private, employer‐sponsored health insurance in the United States. We included adults (≥ 16 years) with OUD who initiated and completed at least 30 consecutive days of buprenorphine treatment between July 2017 and June 2019, with a 180‐day follow‐up. Group‐based trajectory modelling identified distinct adherence patterns. Multinomial logistic regression examined predictors of adherence trajectories. A discrete‐time survival model estimated the association between adherence and opioid overdose risk, while generalised linear models assessed healthcare costs. Sensitivity analyses, including E‐value calculations, evaluated residual confounding. Results: Among the 5107 individuals (median [Q1‐Q3] age in years: 37 [26–47]; 3185 [62.4%] male), three distinct buprenorphine adherence trajectories were identified in the follow‐up period: consistent adherence (CA, 49.5%), slow‐declining adherence (SDA, 28.0%) and rapidly‐declining adherence (RDA, 22.5%) trajectory groups. The mean (95% CI) time to buprenorphine discontinuation among all beneficiaries was 153 (151–155) days. Compared to the CA group, SDA and RDA groups had 2.74 (95% CI 2.71–2.77) and 3.81 (95% CI: 3.76–3.86) times higher opioid overdose risk and $13,670 (95% CI $7644–$19,695) and $19,431 (95% CI $13,632–$25,229) higher healthcare spending, respectively. Discussion and Conclusions: Consistent adherence to buprenorphine was associated with a lower risk of opioid overdose and reduced healthcare expenditures.
- Open Access
- 15 July 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 16, 100360
Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel
- 15 July 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 16, 100360
Open AccessAddressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel
- 3 April 2025
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 21 (2) , 142-151
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation
Objective: The relationship between concurrent depression and Opioid Use Disorder (OUD) treatment outcomes remains incompletely understood. Prior studies found mixed results regarding the impact of psychiatric comorbidities on retention to medications for OUD. This study aims to evaluate how the receipt of pharmacotherapy for depression impacts retention to buprenorphine therapy among patients with OUD and concurrent depression. Methods: We conducted a retrospective cohort study using the Humana Healthcare Research claims database (2014-2020) on a sample of adult patients who initiated buprenorphine for OUD between January 2015, and September 2019. Patients were required to have a 180-day buprenorphine-free period pre-index. Patients with concurrent depression were identified via diagnosis in a medical claim within the baseline period. Antidepressant use was defined as cumulative exposure from the start of the baseline through the end of the 180-day follow-up period. The primary outcome was time to buprenorphine discontinuation, defined as a gap of more than 30 days from the day of last supply. Cox Proportional Hazards regression was used to estimate the association between antidepressant receipt and buprenorphine discontinuation. Sensitivity analyses on specific classes of antidepressants were also conducted. Results: The final analytical cohort included 1,973 patients with OUD and concurrent depression. Of these, 235 (11.91%) discontinued buprenorphine during the follow-up period, with a mean time to discontinuation of 97.92 (±68.64) days. Survival analysis revealed that patients who received antidepressants had a significantly lower hazard of discontinuation [aHR (95% CI): 0.995 (0.994, 0.996); p < .0001]. Initiated dose of buprenorphine also had a significant effect on the hazard of discontinuation [0.976 (0.956, 0.997); p = .0270]. Conclusions: Our findings support the notion that continuation of antidepressants when initiating buprenorphine therapy for OUD positively influences buprenorphine retention among patients with OUD and concurrent depression.
- 3 April 2025
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 21 (2) , 142-151
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation
Objective: The relationship between concurrent depression and Opioid Use Disorder (OUD) treatment outcomes remains incompletely understood. Prior studies found mixed results regarding the impact of psychiatric comorbidities on retention to medications for OUD. This study aims to evaluate how the receipt of pharmacotherapy for depression impacts retention to buprenorphine therapy among patients with OUD and concurrent depression. Methods: We conducted a retrospective cohort study using the Humana Healthcare Research claims database (2014-2020) on a sample of adult patients who initiated buprenorphine for OUD between January 2015, and September 2019. Patients were required to have a 180-day buprenorphine-free period pre-index. Patients with concurrent depression were identified via diagnosis in a medical claim within the baseline period. Antidepressant use was defined as cumulative exposure from the start of the baseline through the end of the 180-day follow-up period. The primary outcome was time to buprenorphine discontinuation, defined as a gap of more than 30 days from the day of last supply. Cox Proportional Hazards regression was used to estimate the association between antidepressant receipt and buprenorphine discontinuation. Sensitivity analyses on specific classes of antidepressants were also conducted. Results: The final analytical cohort included 1,973 patients with OUD and concurrent depression. Of these, 235 (11.91%) discontinued buprenorphine during the follow-up period, with a mean time to discontinuation of 97.92 (±68.64) days. Survival analysis revealed that patients who received antidepressants had a significantly lower hazard of discontinuation [aHR (95% CI): 0.995 (0.994, 0.996); p < .0001]. Initiated dose of buprenorphine also had a significant effect on the hazard of discontinuation [0.976 (0.956, 0.997); p = .0270]. Conclusions: Our findings support the notion that continuation of antidepressants when initiating buprenorphine therapy for OUD positively influences buprenorphine retention among patients with OUD and concurrent depression.
- Open Access
- 18 December 2024
- Published by Elsevier in Leukemia Research Reports
- Vol. 23, 100496
Retrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019
- 18 December 2024
- Published by Elsevier in Leukemia Research Reports
- Vol. 23, 100496
Open AccessRetrospective claims data analysis of ASCT characteristics and costs for working-age, multiple myeloma patients in the US, 2017–2019